Compare INMB & SBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INMB | SBI |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 111.7M |
| IPO Year | 2018 | N/A |
| Metric | INMB | SBI |
|---|---|---|
| Price | $1.15 | $7.56 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.87 | N/A |
| AVG Volume (30 Days) | ★ 430.5K | 31.3K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,000.00 | N/A |
| Revenue This Year | $264.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $7.30 |
| 52 Week High | $11.64 | $8.01 |
| Indicator | INMB | SBI |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 23.24 |
| Support Level | N/A | $7.53 |
| Resistance Level | $1.48 | $7.91 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 1.56 | 5.88 |
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager.